Cargando…
Zoledronic Acid Is Not Equally Potent on Osteoclasts Generated From Different Individuals
Zoledronic acid is a bisphosphonate commonly used to treat bone diseases such as osteoporosis and cancer‐induced bone disease. Patients exhibit a variable sensitivity to zoledronic acid; the underlying explanation for this remains unclear. The objective of this study was to obtain more knowledge in...
Autores principales: | Møller, Anaïs M J, Delaisse, Jean‐Marie, Olesen, Jacob B, Bechmann, Troels, Madsen, Jonna S, Søe, Kent |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7657394/ https://www.ncbi.nlm.nih.gov/pubmed/33210064 http://dx.doi.org/10.1002/jbm4.10412 |
Ejemplares similares
-
A variability in response of osteoclasts to zoledronic acid is mediated by smoking-associated modification in the DNA methylome
por: Tan, Qihua, et al.
Publicado: (2023) -
Aging and menopause reprogram osteoclast precursors for aggressive bone resorption
por: Møller, Anaïs Marie Julie, et al.
Publicado: (2020) -
Fusion Potential of Human Osteoclasts In Vitro Reflects Age, Menopause, and In Vivo Bone Resorption Levels of Their Donors—A Possible Involvement of DC-STAMP
por: Møller, Anaïs M. J., et al.
Publicado: (2020) -
Osteoclast Fusion: Time‐Lapse Reveals Involvement of CD47 and Syncytin‐1 at Different Stages of Nuclearity
por: Møller, Anaïs Marie Julie, et al.
Publicado: (2016) -
Time-lapse reveals that osteoclasts can move across the bone surface while resorbing
por: Søe, Kent, et al.
Publicado: (2017)